Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The activity and tolerability of Aromatase inhibitor plus PI3KCA inhibitor or CDK4/6 inhibitor in women with hormone receptor positive recurrent/metastatic gynaecological neoplasms (PARAGON-II)

Next Previous
Trial Profile

The activity and tolerability of Aromatase inhibitor plus PI3KCA inhibitor or CDK4/6 inhibitor in women with hormone receptor positive recurrent/metastatic gynaecological neoplasms (PARAGON-II)

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alpelisib (Primary) ; Letrozole (Primary) ; Ribociclib (Primary)
  • Indications Carcinoma; Endometrial cancer; Fallopian tube cancer; Gynaecological cancer; Leiomyosarcoma; Ovarian cancer; Peritoneal cancer; Sarcoma
  • Focus Therapeutic Use
  • Acronyms PARAGON-II

Most Recent Events

  • 13 Jan 2022 Planned End Date changed from 31 Jul 2024 to 1 Nov 2024.
  • 13 Jan 2022 Planned initiation date changed from 31 Jul 2021 to 1 Feb 2022.
  • 02 Jun 2021 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top